Molecule to Market: Inside the outsourcing space

Top 5 episodes of all time

As we celebrate the podcast hitting 30,000 downloads and approaching its 100th episode, Raman reflects on the most downloaded episodes with highlights from the top 5.  

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector, diving into the top 5 episodes of all time, featuring:

• JoyL Silva, Pfizer CentreOne discussing: her early career journey and advice, industry trends, and personalized medicines
• Tia Lyles-Williams, LucasPye Bio discussing: equality & diversity, Covid-19’s impact, fundraising and providing opportunities to the next generation  
• Gerry Cox, Velesco Pharma Services discussing: client relationships, starting a new business and his advice 
• Cory Lewis, INCOG BioPharma discussing: acquisitions, turning around a business, and lessons from the franchise model 
• Allan Shaw, Industry Consultant discussing: biotech trends, commonalities & challenges, and the supply chain ecosystem

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

CPHI 2022 - Trends, challenges & opportunities

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who discusses emerging trends and challenges for the life sciences sector live from CPHI Frankfurt 2022, with:

• Grainne Hughes, Vice President of Business Support Operations at Almac 
• Christine Fürst, Senior Director Key Account Manager Europe at Vetter Pharma 
• Guido Wallraff, Corporate Business Development Director at Ardena
• Jenny Gattari, CDMO Business Development Lead (North America) at Pfizer CentreOne 
• Brittany Hayes, Director of Global Highly Potent & Oncology Platform at CordenPharma

Listen to this episode to find out more about these companies and gain an insight into the changes and demands they see coming in 2023. They also discuss their experience of CPHI this year, how it compares to last year’s event and what trends they have noticed across their exploration of the Messe. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Views from AAPS 2022

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who discusses future industry trends live from AAPS Boston 2022, with:

• Casey Franklin, VP of Business Development at Alcami

• Umberto Romeo, R&D Manager at Corden Pharma

• Steven Dodd, Executive Director for sales strategy at Icon CRO

• Paul Dickinson, Founder & CSO at Seda Pharmaceutical Development Services

Raman finds out more about the exciting opportunities coming up for these companies in 2023 and beyond, as well as scoring the inside scoop on trends our guests foresee both within their business and the wider industry. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

The Personalized Medicine Pioneer

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with David Katz, Founder & CSO at Sparrow Pharmaceuticals, Inc.Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering:

• The contrast of developing new drugs and running clinical trials in a big pharma versus his journey as the founder of a virtual biopharma company.
• What life really looks like and skills you have to develop in a firm developing novel, targeted therapies to address unmet patient needs.
• Some of the options, decisions and pathways to commercialization that a Phase 2 biopharma business has to consider.
• The inspiration, leadership learnings and brand influence of a famous Hollywood character.

Prior to founding Sparrow, David was a pharmaceutical R&D leader at Abbott and AbbVie, where he led clinical development and drug discovery teams, and was a personalized medicine pioneer. David is dedicated to the mentorship of the next generation of life sciences entrepreneurs, currently as an entrepreneur-in-residence at Oregon Health & Science University. He held post-doctoral fellowships in immunology at the Universities of Chicago and Michigan, earned MPhil and PhD degrees in Molecular Biophysics and Biochemistry from Yale University, and is an alumnus of Pomona College (BA, Chemistry). David has published over 50 peer-reviewed scientific papers and in his copious spare time, he is actively involved in new play development and is a glass artist.

Don't forget to subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

 

Inizio’s biotech bromance

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jason McKenna, Global President, and Dean McAlister, Executive Vice President both from Inizio Biotech.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with the dynamic duo, covering:

• A wealth of big pharma learnings for today’s emerging biotechs.
• The (good and bad) impact of the current biotech capital market slowdown on decision-making for outsourced service providers.
• What the future may look like in our space in terms of financing and therapeutic impact.
• Learnings from how to make a business relationship successes from complementary colleagues.

Jason spent the initial part of his career in big pharma, working for AstraZeneca in the US and UK across a variety of marketing, sales and finance roles. He is now the Global President of Inizio’s first enterprise business unit, Inizio Biotech. Jason and his team enable biotech partners to maximize the value of their assets by providing scalable support, through the seamless experience of a single point of coordination. Previously CEO at STEM, an Inizio Advisory company, Jason led the organization through significant scaling and transformation throughout the COVID pandemic.

Dean has over 35 years of biopharma experience across established and startup organizations – including 28 years with AstraZeneca in 16 roles of increasing commercial responsibility, where he led global and regional sales and strategic business development. Dean has built cross-functional teams spanning all therapeutic areas. Following AZ, he grew STEM Healthcare North America from 10 clients to 38 over a five-year period before a sale to UDG. He is also a podcaster, speaker, and published author.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

The Magic of Drug Development

In this special episode of Molecule to Market, we go back inside the global drug development space with Marcelo Bigal, President and CEO, of Ventus Therapeutics, and Versant Venture Partner, who shares his journey from being a neurologist to taking a drug to market when he became part of Teva Pharmaceuticals and now is a CEO.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Marcelo, covering: 

• What it feels like to take a drug from the laboratory to market and what really goes into that process.
• The company’s phenomenal attitude toward patients and how this is exemplified in its drug development. 
• The incredible story of the company he joined and how 14 months after a fundraiser it was acquired by Teva Pharmaceuticals for $825M.
• The current state of the capital market and where future opportunities may lie for the business. 
• The challenging area of drug development in biotechnology over the last three years. 

Marcelo brings more than 13 years of pharma experience with a focus on urology spanning r&d, medical and scientific affairs. He has extensive experience in leading large and small scientific groups, including multiple leadership roles in industry, including the Chief Scientific Officer at Teva as well as Chief Medical Officer at Teva and Purdue. Prior to his work in the pharma sector, Marcelo was a faculty member of the Albert Einstein College of Medicine, Department of Neurology, as well as the director of research at the New England Centre for headache. 

He has authored no fewer than 330 papers in peer-reviewed journals, edited six books in urology and is the recipient of multiple awards and recognitions in the field. Marcelo holds a medical doctorate degree from the College of Medicine at the University of Sao Paulo, Brazil, where he obtained a master’s in science and a PhD in neurosciences. He completed his postdoctoral research at the New England Centre for headache.

Why everything starts with great culture

In this special repurposed episode of Molecule to Market, we go back inside the global drug development space with previous guests Magnus Gustafsson, Board Member at Genovis, Jeff Dill, CEO at Vynamic. , and Peter Soelkner, Managing Director at Vetter to hear their thoughts on building a great organisational culture. 

Your host, Raman Sehgal, revisits discussions from past episodes, with amazing global guests who share their insights about building culture to give our listeners loads of takeaway points, from episodes including:

• Finland’s Viral Vector Manufacturer of Happinesses
  
  Hear from Magnus Gustafsson – who Raman describes as a delightful gentleman that remains passionate about his purpose. His curiosity has enabled him to take real pleasure from working across complex projects. Magnus cites investment into company culture as crucial to developing a great company and building a solid NPS score, commenting: ‘you need some of your own skin in the game’.

• Creating a healthy culture
  
  It’s no secret Jeff Dill is a favourite guest of Raman’s. During the pandemic they enjoyed a great conversation about culture and team work. Jeff firmly believes in prioritizing people and talks in detail about Vynamic’s ‘vitals’ – a document that incapsulates the company’s purpose and a series of values. The vitals provide consistency and a foundation to scale and build. He talks about doubling down on what works well to enable people to bring their whole selves to work everyday. What a great approach!

• From Pharmacy to $1B family-owned CDMO
  
  Finally, we hear from Peter Soelkner who contributed to one of our most successful podcast shows. We listen back to hear about Vetter’s phenomenal success in the US and Germany, and Peter’s fascinating thoughts on culture. From Vetter’s humble beginnings to earning a fantastic reputation in the space Peter talks candidly about the attributes and the people component that make the company so successful. Peter believes you should never look at how far you fell but instead at how high you will jump back up! 

Raman enjoyed the original conversations and took pleasure in listening back to bring you this special culture themed episode. It’s clear our guests all agree that culture is key to developing and scaling a great organization.

We’d love to know what you thought of this special repurposed episode and if you’d like us to develop more of them? Please share your thoughts with us and of course subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

The orphan drug entrepreneur

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Evelyn Kelly, Chief Executive Officer at Orphan Drug Consulting. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Evelyn, covering:

• A deep dive into the world of orphan drugs, rare diseases and personalised medicines including the background, evolution and fast growth of the area.
• The revolution in drug development that we are living right now and what this means for CROs, CDMOs and vendors in the space.
• The scary phase of being a start up along with the importance of having purpose as your motivation and being prepared to step-up.
• The non-covid impact of covid of the health of the population and the set-back it caused for small biotechs.
• Pearls of wisdom for ambitious young female leaders navigating their careers in the pharma and biopharma space.

Evelyn has over 15 years’ experience in the pharmaceutical industry in both distribution and orphan drug companies, working across supply chain, quality assurance and management roles. Evelyn brings years of experience in manufacturing and distributing orphan and speciality drugs to over 50 countries globally.She specializes in the management of supply via virtual, outsourced models and has been named as both a QP and RP on multiple licenses. She has held various positions in Shire, NPS Pharma and PTC Therapeutics and has designed and ran successful supply chains for different products.Evelyn founded Orphan Drug Consulting in 2017, with the vision of supporting companies across the drug development cycle. She holds a Master of Pharmacy from Robert Gordon University and a Master of Business from the Irish Management Institute. She also acts as Adjunct Associate Professor for the School of Pharmacy, Trinity College, Dublin. In 2022, she was named as a finalist in EY Entrepreneur of the Year.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

The wonder of Wurster technology

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Chuck Frey, VP Scientific Affairs at Coating Place. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Chuck, covering:

• The backstory to Wurster coating technology and how it changed the world of formulation development.
• Being the go-to guys for the most challenging processing projects... when no one else in the market can.
• The advantages and disadvantages of going under the radar.
• Ups, downs, sacrifices and successes of family life while working in the industry.

Charles (Chuck) Frey is the Vice President of Scientific Affairs at Coating Place, Inc., a CDMO focused in Wurster (bottom spray) fluid bed coating and associated services.Chuck moved on to Coating Place, Inc. in 1999 to develop expertise on the Wurster fluid bed coating process. During his time at Coating Place, Chuck has focused primarily on application of the Wurster process and related technologies to meet the feasibility, formulation development, scale up, validation, and commercial processing needs of clients. Primary interests have included both formulation chemistry and optimization of process dynamics. The company continues to manufacture proprietary Wurster coating equipment for its operations and Chuck has helped maintain and expand the company’s offer with new fluidization plate designs, new nozzles, enhanced scaling knowledge, and other technical advancements. Having spent over 30 years in the sector, Chuck has also lectured on the Wurster process and formulations, and contributed several book chapters on the fluid bed coating processes and formulations.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Biotech trends you need to know

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Allan Shaw, Consulting CFO, Special Advisor & Board Member of several biotech companies. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Allan, covering:

• The sensitive cash position of biotech's as a ‘hangover’ after a decade of partying as the market was high.
• The potential domino effect and collateral impact of the biotech capital slowdown on the supply chain ecosystem.
• Core commonalities between biotech's of all shapes and sizes, and what challenges they face today.
• How CRO/CDMO and other pharma services’ vendors can add the most value during an expected bumpy ride for biotech's.

Allan is a senior biopharmaceutical executive and board member with 20+ years of international and transactional experience. He is a five-time public company CFO and has served on six public boards, which included the chairing of two audit and two compensation committees. He is currently involved with a portfolio of healthcare activities, including serving as Portage Biotech’s Chief Financial Officer. Prior, Shaw also served as managing director and life science practice leader for Alvarez & Marsal’s healthcare industry group. He was also CFO at Serono.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.